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43 yo woman presents for health maintenance. She is 
nulliparous, premenopausal and had an aunt who was 
diagnosed with breast cancer at 67y. She would like to 
know when she should start screening mammograms 
and how often.
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Aims:
• Review factors influencing breast cancer risk
• Discuss the evidence behind the most recent 
screening guidelines for mammography
• Describe other screening modalities, and their pros 
and cons
• Discuss recommendations for screening high risk 
women
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BREAST CANCER RISK 
FACTORS
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Risk Factors - SEX
Age-standardized 
rates (ASR) with 
the estimated 
annual percentage 
changes in the ASR 
for male and female 
breast cancer 
incidence rates. 
Anderson W F et al. JCO 2010;28:232-239
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Risk Factors - AGE
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Risk factors - RACE
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Risk factors –
HORMONAL/REPRODUCTIVE
Factor Effect on risk
Menopause > 55yrs ↑ by 2
First menstruation < 
12 yrs
↑ by 4
Never pregnant ↑ by half 
Late first pregnancy ↑ by 2
Hormone 
replacement therapy
↑ by 2
Breast feeding ↓ by about 10%
Oral contraceptives ↑ by 24%
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Risk Factors –
LIFESTYLE/MEDICAL HISTORY
Risk factor Effect on risk
Postmenopausal
obesity
↑by 2
Alcohol use
(≥1glass/dy)
↑ by about 30%
Personal history of 
breast cancer
↑ by 2-3
History of chest 
radiation at a young 
age
↑ by 10-15
Prior breast biopsies Depends (2-8 fold 
increase)
Dense breasts on 
mammography
↑ by 2-5 
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Breast density
10% 40%40% 10%
5 risk
(Are you dense?)
10% 40% 40% 10%
5xrisk2xrisk
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Risk factors –
Family History
Only 20% of women with breast cancer have a 
family history; but women with a family history 
have a higher risk of breast cancer
Mother/sister/daughter: risk ↑x2
Mother and sister: risk ↑ x3.5
Aunt/cousin/grandma: risk ↑by 50%
Risk is affected by number and age of relatives with cancer
About 2% of familial 
cancers are caused
by a specific
hereditary mutation
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BRCA 1 and 2 mutation
• 0.1% of the population have 
the mutation
• Breast cancer risk is 48-76% 
lifetime 
• Genetic counseling indicated 
when there is a ≥10% 
probability of the mutation
• Testing cost $3400
• Thresholds required to ensure 
insurance coverage
• Genetic Information 
Nondiscrimination Act (GINA) -
2008
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Who should get testing?
NCCN guidelines
• Known family history of mutation
• Personal h/o breast cancer and:
• Age <46yr
• Bilateral breast cancer
• Age <60 and triple negative breast cancer
• Dx < 50y with 1 or more relatives with 
BC/OC
• Dx any age with 2 or more relatives with 
BC/OC
• Dx any age with 1 or more relative dx 
<50yrs
• Dx any age with 2 or more relative with 
pancreatic/prostate
• Dx any age with 1 or more relative with 
ovarian Ca
• Personal history of ovarian cancer
• Male breast cancer
• Pancreatic cancer or prostate 
cancer < 50y with ≥ 2 relatives with 
breast/ovarian/pancreatic cancer
• Family history only
• 1st/2nd degree relative meeting any 
above criteria
• Third degree relative with breast/ovarian 
with ≥ 2 close relatives with 
breast/ovarian (at least 1 under 50yrs)
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Models for calculating risk
Germline Mutation Risk Prediction 
Models
• BRCAPRO
• BOADICEA (Breast 
and Ovarian Analysis of 
Disease Incidence and 
Carrier Estimation 
Algorithm)
• IBIS
• Myriad II 
• Manchester
• Penn II
Breast Cancer Risk Assessment 
Models
• Gail
• Claus
• Tyrer-Kuzik
• Jonker
• BCSC 
(https://tools.bcscscc.org/BC5year
Risk/calculator.html)
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Modified Gail model risk assessment tool
http://brca.nci.nih.gov/brc
6  breast cancer risk factors
• Age
• hormonal or reproductive history (age at 
menarche and age at first live birth)
• previous history of breast disease (number 
of breast biopsies and history of atypical 
hyperplasia)
• family history (number of first-degree 
relatives with breast cancer). 
High risk ≥ 20% lifetime risk or ≥ 
1.7% 5 yr risk
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Limitations of risk prediction models
• Adoption, small family 
size 
• Lack of information/ 
inaccurate information 
about family history 
• Only includes 1st and 2nd
degree relatives
• Other cancers not 
included
• Population specific details 
not included
• Reliance on known risk 
factors (60% of breast 
cancers occur in the 
absence of known risk 
factors)
• Not all risk factors 
included
• Less accurate for patient 
different from the source 
data population
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RISK IS ASSESSED
NOW WHAT?
5 yr risk: 0.8%
Lifetime risk 10.8% 
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SCREENING IN 2016
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ACS/ACR screening guidelines 1980
All women should begin 
annual screening 
mammography at age 40yrs.
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Screening recommendations galore
United States Preventative Task 
Force 2016
• Biannual screening
• Start at age 50y
• End at age 75y
• No self breast exam 
(2002)
• Screening before age 50y 
individual decision.
• Insufficient evidence to 
recommend for or against
• Screening after 75y
• Screening before age 50y
• Clinical breast exam (2002)
American Cancer Society 
Recommendations 2015
• Annual screening from 
45-55y, then biannual as 
long as 10yr life 
expectancy
• Women <45y should have 
the opportunity to screen 
• Women >55y should have 
the opportunity to 
continue annual screening
• No clinical breast exam
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The anatomy of a screening guideline
Benefits
Harms
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Harms
• Anxiety and worry associated with a false positive 
diagnosis
• Discomfort and other adverse consequences of a 
negative biopsy
• Over diagnosis
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Age Specific Screening Outcomes
Outcome: n per 1000 
women screened
40-49 50-59 60-69 70-79
False-positive mammography 121.2 93.2 80.8 69.6
Additional imaging
recommended
124.9 98.5 88.7 79.0
Biopsy recommended 16.4 15.9 16.5 17.5
Screen-detected invasive 
cancer
2.2 3.5 5.8 7.2
Screen detected DCIS 1.6 1.8 2.1 2.3
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10 yr probability of false positive 
mammography based on age
0
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9
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age 40 at first
screening
age 50 ato first
screening
7
9.4
4.8
6.4
annual biennial
Risk of  false positive recall:
16.5% at first mammo
9.5% at subsequent mammo
Risk of recommendation for 
false positive  biopsy:
2.5% at first mammo
1.5% at subsequent mammo
Hubbard et al, Ann Intern Med, 2011
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Lisa M Schwartz , Steven Woloshin Harold C Sox Baruch Fischhoff H Gilbert Welch
Veterans Affairs Outcomes Group (111B)  Veterans Affairs Medical Center
White River Junction, VT 05009
63% of women felt that 500 false positives 
per life saved was acceptable.
37% felt that 10,000 false positives per life 
saved would be acceptable
62% did not think that false positives should 
affect decision making about mammography
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Overdiagnosis
• The identification of a screen-detected cancer that would 
not have led to symptomatic breast cancer if undetected 
by screening.
• Associated with overtreatment
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Key finding:
15% to 25% of 
cases of cancer are 
over diagnosed, 
translating to 6 to 
10 women over 
diagnosed for every 
2500 women 
invited.
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How much overdiagnosis?
Type of 
study
# of studies Summary of Findings
Proportion of new 
cancers representing 
diagnosis
Absolute risk of 
overdiagnosis
Randomized 
controlled 
trials
Cochrane review 
(7 trials)
29% Not estimated
UK independent 
review (2 trials)
10.7-19% Not estimated
Cohort
studies 
18 studies, 
including 1 
evaluating 
interval of 
mammo
Range 0-54% 6.0% higher with  
biennial in premen. 
women
7.7% lower with 
biennial in postmen 
women
Model 1 Biennial  less 
overdiagnosis than 
annual by “much less 
than half”
Not estimated
Wide 
variability in 
methodology 
and 
estimates
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BENEFITS OF 
MAMMOGRAPHY
MORTALITY
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AGE AT FIRST 
MAMMOGRAM
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Efficacy by age
• Mammography is roughly equally effective, on a relative 
basis, in all age groups
• 20% reduction in age-adjusted mortality rates based on 
randomized trials
• 27-40% reduction based on modern day observational trials
• The balance of benefits and drawbacks is largely a 
function of the risk of breast cancer in each age group
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Breast Cancer risk in younger women
Age
(year
s)
Incidenc
e rate 
per 
100,000
Probability of 
being diagnosed in 
the 1 yr interval
% of BC 
deaths by 
age  at 
diagnosis.% 1 in N
35 44.9 0.0% 2,212 1%
36 51.9 0.1% 1,943 1%
37 61.6 0.1% 1,713 1%
38 65.9 0.1% 1,440 1%
39 79 0.1% 1,232 1%
40 106.3 0.1% 1,076 1%
41 109.8 0.1% 954 1%
42 120.9 0.1% 857 1%
43 130.6 0.1% 774 1%
44 148.3 0.1% 706 2%
45 165.9 0.2% 648 2%
a. Delay adjusted incidence rates, SEER18, 2008-2012
Risk between 
ages 40-41 is 
9 in 10,000.
The recall
rate is 1,600-
2,000 per 
10,000 (about 
1in 5).
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Breast Cancer Burden by Age at 
Diagnosis for the Period 2007-2011
6
%
12%
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12%
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SCREENING INTERVAL
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What determines screening interval?
• Screening interval is NOT a function of risk
• Screening interval should be determined by the 
rate of progression of cancer or pre-cancer
• Many screening intervals have been widening 
(Pap smear, PSA)
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10 yr probability of false positive 
mammography based on age
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age 40 at first
screening
age 50 ato
first screening
7
9.4
4.8
6.4
annual biennial
Risk of  false positive recall:
16.5% at first mammo
9.5% at subsequent mammo
Risk of recommendation for 
false positive  biopsy:
2.5% at first mammo
1.5% at subsequent mammo
Hubbard et al, Ann Intern Med, 2011
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Supplemental Analysis of Screening 
Interval from NCI-Funded Breast Cancer 
Surveillance Consortium
Breast Tumor Prognostic Characteristics and Biennial 
vs Annual Mammography, Age, and Menopausal 
Status.
Miglioretti DL, Zhu W, Kerlikowske K et al. JAMA Oncol. 2015 
Nov;1(8):1069-77. 
• prospective cohort of 15,440 women ages 40 to 85 years from 
1996 to 2012 
• Patients had breast cancer diagnosed within 1 year of an 
annual or within 2 years of a biennial screening mammogram.
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Supplemental Analysis of Screening Interval 
from NCI-Funded Breast Cancer Surveillance 
Consortium
Premenopausal women
Biennial screening 
associated with
• More advanced stage disease 
(RR 1.28)
• Larger tumors (RR 1.21)
• Less favorable prognostic 
characteristics (RR 1.11)
Postmenopausal women
• No difference in tumor 
size, stage or 
characteristics between 
annual and biennial 
mammography.
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BREAST EXAM
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Clinical breast exam
• Trials of clinical breast exam and mammography 
did not show benefit compared to mammography 
alone.
• ASC concluded “CBE not effective for screening” 
in the settings where mammography is available.
• Retrospective studies of clinician detected breast 
masses find that only 30-50% of these have an 
anatomic correlate, the majority of which are not 
cancer.
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Breast Self-Examination
• BSE has been removed from guidelines for routine 
breast cancer screening (USPSTF, NCI)
• Based on 3 major studies:
• large RCT from Shanghai, China - no difference in breast 
cancer mortality after 11 years in factory workers randomly 
assigned to BSE and follow-up versus a control group
• UK group – 16 yrs of followup
• World Health Organization/Russia trial – BSE taught at 
work, no difference at 11 yrs f/u
• NCI concluded a higher biopsy rate with no 
improvement of survival; however, compliance in all 
studies was low.
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Screening in high risk patients
• ACS recommendation for ‘ for all women without 
genetic mutation or previous chest radiation at a 
young age.’
• No differentiation of risk by prior h/o atypia, family 
history, mammographically dense breasts
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Surveillance of high risk women
ACR guidelines - Mammography
• BRCA1 or BRCA2 mutation carriers: by age 30, but not 
before age 25
• Women with 1st degree relative with pre-menopausal BC: by 
age 30 but not before age 25, or 10 years earlier than the age 
of diagnosis of relative, whichever is later
• Women with ≥20% lifetime risk for breast cancer by FH: 
yearly starting by age 30 but not before age 25, or 10 years 
earlier than the age of diagnosis of the youngest affected 
relative, whichever is later
• Women with histories of mantle radiation b/w 10-30yrs: 
beginning 8 years after the radiation therapy but not before age 
25
• Women with biopsy-proven lobular neoplasia, ADH, DCIS, 
invasive breast cancer, or ovarian cancer regardless of age
These materials provided for reference use at the 43rd Annual Family Medicine Refresher Course for the Family Physician. 
Permission from the author must be sought before reuse or redistribution.
Tomosynthesis
• 3D 
mammography
• Improved 
detection of 
cancers in 
dense breasts
• Decreased call 
backs for more 
images
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• 281, 187 digital mammograms (DM) compared to 173,663 
digital mammograms + tomosynthesis(DMT) in 13 breast 
centers
• Recall rate 107 vs 91/ 1000 screens with DM vs DMT
• Cancer detection 4.2 vs 5.2/ 1000
• Invasive cancer detection 2.9 vs 4.1/1000
• Positive predictive value for recall 4.3% vs 6.4%
Friedewald et al. JAMA 2014
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Screening MRI
Who should have screening MRI?:
ACR Recommendations
1) Women with BRCA mutation
∘Annually starting by age 30
2) Untested first-degree relatives of 
women with BRCA mutations
∘Annually starting by age 30
3) Women with >20% lifetime risk for 
breast cancer 
∘Annually starting by age 30
4) Women with histories of chest 
irradiation before 30yrs
∘Annually starting 8 years after 
the radiation therapy
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Automated Whole Breast Ultrasound
• Useful for intermediate risk women with heterogeneously or 
very dense breasts, or high risk women unable or unwilling to 
have MRI
• ACRIN study – 4.3 additional invasive BC/ 1000 women (dense 
breasts)
• NOT meant to replace mammography as a screening tool
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From: Supplemental Screening for Breast Cancer in Women With Dense 
Breasts: A Systematic Review for the U.S. Preventive Services Task Force
Ann Intern Med. 2016;164(4):268-278. doi:10.7326/M15-1789
24 studies from 7 countries; only 6 ‘good quality’
Looked at performance of screening breast US, MRI 
and digital breast tomosynthesis
Ultrasound: Sensitivity of US for women with negative mammos
75-100%, specificity 86-94%
Additional cancer detection by US = 4.4/1000 exams, recall rates 
14%
MRI: 3.6 to 28.6 additional cancer/1000 exams; recall rates 14-
24%
Tomosynthesis: 1.4-2.5 additional cancers/1000 exams; lower 
recall rates than digital mammo
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Where to next?
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Questions?
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